Telisotuzumab vedotin
- Generic Name
- Telisotuzumab vedotin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1714088-51-3
- Unique Ingredient Identifier
- 976X9VXC3Z
- Background
Telisotuzumab vedotin is under investigation in clinical trial NCT02099058 (A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Subjects With Advanced Solid Tumors.).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Phase 3
Recruiting
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-06-16
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 698
- Registration Number
- NCT04928846
- Locations
- 🇨🇳
Mackay Memorial Hospital /ID# 238392, Taipei City, Taiwan
🇨🇳Taipei Medical University Hospital /ID# 238380, Taipei City, Taiwan
🇹🇷Memorial Ankara Hastanesi /ID# 234212, Çankaya, Ankara, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath